Inspra Contraindications

Eplerenone is contraindicated in all patients with the following: Hypersensitivity to eplerenone or any component of this medication.
Clinically significant hyperkalemia or with conditions associated with hyperkalemia.
Serum potassium level >5.0 mmol/L (mEq/L) at initiation.
Moderate to severe renal impairment (creatinine clearance <50 mL/min) in post MI heart failure (Eplerenone Post-acute Myocardial Infarction Heart failure Efficacy and Survival Study [EPHESUS]) or creatinine clearance of ˂30 mL/min in NYHA Class II (chronic) heart failure (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure [EMPHASIS-HF]).
Severe hepatic impairment (Child-Pugh Class C).
Concomitant use with potassium-sparing diuretics, or potent inhibitors of CYP450 3A4 such as ketoconazole, itraconazole, and ritonavir, (see Interactions).
Eplerenone is also contraindicated in hypertensive patients with the following conditions: Type 2 diabetes with microalbuminuria.
Serum creatinine >2.0 mg/dL (or >177 µmol/L) in males or >1.8 mg/dL (or >159 µmol/L) in females.
Concomitant use with potassium supplements.